The miRNA-drug resistance connection: A new era of personalized medicine using noncoding RNA begins

Pharmacogenomics

Volumn 13, Issue 12, 2012, Pages 1321-1324

  Mishra, Prasun J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

diagnosis; disease; drug resistance; epidemiology; genetic variation; genomic medicine; individualized medicine; microRNA; miRNA; miRSNP; mutations; ncRNA; noncoding RNA; personalized medicine; pharmacogenomics; polymorphisms; prognosis

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEFITINIB; HYDROXYUREA; INTERFERON; LAPATINIB; METHOTREXATE; MICRORNA; MICRORNA 130A; MICRORNA 15B; MICRORNA 16; MICRORNA 200C; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 27A; MICRORNA 34A; MICRORNA 451; MITOXANTRONE; NOGALAMYCIN; PACLITAXEL; PLATINUM COMPLEX; TAMOXIFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VINBLASTINE;

DOWN REGULATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; OVARY CANCER; PERSONALIZED MEDICINE; PROGNOSIS; REVIEW;

DRUG RESISTANCE; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; RNA, UNTRANSLATED;

EID: 84866315993     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.121     Document Type: Review

References (37)

1. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature 422(6934), 835-847 (2003 (Pubitemid 36520032)
2. Lander ES. Initial impact of the sequencing of the human genome. Nature 470(7333), 187-197 (2011
3. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 294(5543), 862-864 (2001 (Pubitemid 33032105)
4. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006 (Pubitemid 43357945)
5. Bertino JR, Banerjee D, Mishra PJ. Pharmacogenomics of microRNA: A miRSNP towards individualized therapy. Pharmacogenomics 8(12), 1625-1627 (2007
6. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino Jr. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA 104(33), 13513-13518 (2007 (Pubitemid 47293976)
7. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002 (Pubitemid 35403967)
8. Calin GA, Liu CG, Sevignani C et al. microRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 101(32), 11755-11760 (2004 (Pubitemid 39095368)
9. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J. Clin. Invest. 119(8), 2119-2123 (2009
10. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem. 253(5), 1357-1370 (1978 (Pubitemid 8303433)
11. Mishra PJ, Song B, Mishra PJ et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS ONE 4(12), e8445 (2010
12. Blower PE, Chung JH, Verducci JS et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 7(1), 1-9 (2008
13. Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin. Cancer Res. 14(24), 8080-8086 (2008
14. Song B, Wang Y, Xi Y et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28(46), 4065-4074 (2009
15. Kovalchuk O, Filkowski J, Meservy J et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7(7), 2152-2159 (2008
16. Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13(10), 1215-1222 (2008
17. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 284(39), 26533-26546 (2009
18. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111(3), 478-486 (2008
19. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68(2), 425-433 (2008 (Pubitemid 351380068)
20. Xia L, Zhang D, Du R et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 123(2), 372-379 (2008 (Pubitemid 351842022)
21. Garofalo M, Quintavalle C, Di Leva G et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27(27), 3845-3855 (2008 (Pubitemid 351862062)
22. Miller TE, Ghoshal K, Ramaswamy B et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283(44), 29897-29903 (2008
23. Zhao JJ, Lin J, Yang H et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283(45), 31079-31086 (2008
24. Xin F, Li M, Balch C et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25(4), 430-434 (2009
25. Zhu H, Wu H, Liu X et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 76(5), 582-588 (2008
26. Eitan R, Kushnir M, Lithwick-Yanai G et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol. Oncol. 114(2), 253-259 (2009
27. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. 8(5), 1055-1066 (2009
28. DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol. Oncol. 27(3), 307-311 (2009
29. Iorio MV, Casalini P, Piovan C et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69(6), 2195-2200 (2009
30. Li Y, Li W, Yang Y et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res. 1286, 13-18 (2009
31. To KK, Robey RW, Knutsen T et al. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol. Cancer Ther. 8(10), 2959-2968 (2009
32. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 75(6), 1374-1379 (2009
33. Roccaro AM, Sacco A, Chen C et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 113(18), 4391-4402 (2009
34. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15(1), 31-33 (2009
35. Mishra PJ, Bertino Jr. MicroRNA polymorphisms: The future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10(3), 399-416 (2009
36. Mishra PJ. MicroRNA polymorphisms: A giant leap towards personalized medicine. Per. Med. 6(2), 119-125 (2009
37. Mishra PJ, Banerjee D, Bertino Jr. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Cell Cycle 7(7), 853-858 (2008 (Pubitemid 351573776)